Organon & Co. (OGN) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Drug Manufacturers - General
Organon & Co. (OGN) Profile & Business Summary
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Key Information
| Ticker | OGN |
|---|---|
| Exchange | NYSE |
| Official Site | https://www.organon.com |
Market Trend Overview for OGN
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-08-17 (ET)
As of 2026-08-17, OGN is starting to move higher. Over the longer term, the trend remains bullish.
OGN last closed at 13.70. The price is about 0.1 ATR above its recent average price (13.66), and the market is currently in an early upward move. Price at 13.70 is holding above minor support near 13.54. If price continues higher, it may face minor resistance around 13.77. View Support & Resistance from Options
The trend is still positive, but signs of slowing momentum suggest growing two-sided risk.
Trend score: 80 out of 100. Overall alignment is strong. The market is currently in an early-stage uptrend. Trend signals are well aligned across timeframes, suggesting a stable and consistent trend.
A key downside risk boundary is near 13.51. If price falls below this area, the current structure would likely weaken further.
A systematic trend-activation signal was most recently triggered on 2026-04-10, reflecting a technical shift toward positive directional alignment.
[2026-08-10] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
As of 2026-08-14, price has extended significantly above its primary volume area, entering a liquidity-thin zone. While the uptrend remains intact, the risk of chasing strength has increased.
The model sees a bullish edge, with 60.5% upside probability and a still-actionable balance between confirmation and reversal risk.
Up probability is 60.5%, with predictability at 60% and signal agreement at 86%. Reversal risk is 12%, while reward/risk stands at 0.20. That suggests the directional case is supported by broad confirmation and still retains usable quality. At the same time, recent price behavior has shown failed reversal memory.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 18 trading days, with turnover-based decay. The sample period is 2026-07-23 to 2026-08-17. The current price is 13.70, 0.78% above the estimated average cost of 13.59. An estimated 89.6% of recent positioning is below the current price, while 8.7% is above it. The peak-density price is 13.56. The largest concentrated cost region is 13.52 to 13.59 and contains 59.6% of the estimated distribution. The nearest region below the current price is 13.64 to 13.67. The nearest region above the current price is 13.71 to 13.72.
Short Interest & Covering Risk for OGN
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is within its typical range, with no clear imbalance between buyers and sellers. (Historical percentile: 44%)
Structure Analysis
OGN Short positioning looks normal. Current days to cover is 6.2 trading days, meaning short positions would unwind somewhat slower than average. Short covering is likely to have a normal impact on price moves. No meaningful structural fragility is currently detected (Fragility Score 13/100, DTC percentile 71%) as price consolidates near recent highs (20D return 1.6%) with short positioning continuing to expand and liquidity contracting meaningfully (volume -26%).
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
In the latest reporting period, short interest continues to increase. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-07-31 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.